Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Marking 25 Years of Progress in Blood and Marrow Transplantation

December 25th 2015

While major accomplishments in blood and marrow transplantation (BMT) were being made around the country, the first BMT program at Wake Forest Baptist came into view, a vision brought to life by David D. Hurd, MD.

Dr. Stein on Blinatumomab for Relapsed/Refractory ALL

December 22nd 2015

Anthony S. Stein, MD, professor and staff physician, Hematologic Malignancies and Stem Cell Transplantation Institute, City of Hope, discusses a phase II study examining blinatumomab in relapsed/refractory patients with Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia.

Dr. Visani on Tosedostat and Cytarbine in Elderly Patients With AML

December 21st 2015

Guiseppe Visani, MD, director, Hematology and Stem Cell Transplant Center at AORMN, Pesaro, Italy, discusses a phase II study examining the efficacy of tosedostat plus low-dose cytarabine in elderly patients with acute myeloid leukemia.

Live From ASH 2015: Galvanizing Blood Cancer Research!

December 14th 2015

It is obviously impossible to summarize all of the significant data from the 2015 ASH Annual Meeting in this column, but I would like to highlight several key emerging trends that continue to illustrate the palpable ongoing revolution happening in cancer care and beyond.

Dr. Saunthararajah on Mechanisms of Resistance to 5-Azacytidine /Decitabine in MDS-AML

December 10th 2015

Yogenthiran Saunthararajah, MD, Department of Hematologic Oncology and Blood Disorders at Cleveland Clinic, professor of Medicine, co-leader, Developmental Therapeutics Program of the Case Comprehensive Cancer Center, discusses mechanisms of resistance to 5-azacytidine and decitabine in patients with myelodysplastic syndromes-acute myeloid leukemia.

Blinatumomab Shows High CR Rates Across Two ALL Studies

December 9th 2015

Monotherapy with blinatumomab demonstrated high complete remission or CR with partial hematological recovery rates in adult patients with Philadelphia chromosome-positive and -negative B-cell precursor acute lymphoblastic leukemia.

Response Rates Near 100% for CAR T-cell Therapies in ALL

December 8th 2015

Two CD19-targeted chimeric antigen receptor-modified T-cell therapies demonstrated complete response rates ranging from 90% to 100% in patients with high-risk acute lymphoblastic leukemia.

High Response Rates Seen With CAR T-Cell Therapies for NHL

December 7th 2015

Updated findings from early stage clinical trials exploring chimeric antigen receptor-modified T-cell therapies continue to highlight the effectiveness of these approaches for patients with non-Hodgkin lymphoma.

Midostaurin Shows Rare Survival Improvement in FLT3-Mutated AML

December 7th 2015

Patients with FLT3-mutated acute myeloid leukemia lived significantly longer when treated with the multikinase inhibitor midostaurin compared with placebo.

Dr. Steensma on Midostaurin for Patients With AML

December 6th 2015

David P. Steensma, MD, senior physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses a phase III study comparing midostaurin with placebo in combination with daunorubicin cytarabine induction, high-dose cytarabine consolidation, and as maintenance therapy in newly diagnosed patients with acute myeloid leukemia (AML) with FLT3 mutations.

Study Suggests Role for CAR Therapy After Transplant in Advanced B-cell Cancers

December 5th 2015

Gene therapy has the potential to deliver long-lasting remissions for patients with advanced B-cell malignancies who already have undergone an allogeneic hematopoietic stem cell transplant.

Dr. van den Brink Highlights Four Abstracts From ASH 2015

December 3rd 2015

Marcel R.M. van den Brink, MD, PhD, provides an overview of four notable studies being presented at the 2014 American Society of Hematology (ASH) Meeting and Exposition.

June Provides Insight Into Managing AEs From CAR T-Cell Therapies

November 21st 2015

Though clinical work is ongoing and early, researchers are already considering how to manage potentially fatal neurotoxicities in patients treated with chimeric antigen receptor T-cell therapy

New Blood Cancer Landscape Taking Shape

November 12th 2015

Experts discuss developments in CLL, myeloma, and Hodgkin lymphoma.

Ponatinib Plus Chemo: A New Way to Treat Ph-positive ALL

November 10th 2015

Ponatinib is effective against the T315I mutation, which is a leading cuase of resistance, and has shown sustainable responses in patients with Ph+ acute lymphoblastic leukemia.

Dr. Stephen Grupp on Engineered Cell Therapy for the Treatment of Pediatric ALL

November 5th 2015

Stephen Grupp, MD, PhD, director of translational research for the center for Childhood Cancer Research at The Children's Hospital of Philadelphia (CHOP) and medical director of the Stem Cell Laboratory at CHOP, discusses the use of engineered cell therapy for the treatment of Acute Lymphoblastic Leukemia (ALL).

Novel Antibodies Arrive in ALL

November 4th 2015

Monoclonal antibodies are poised to revolutionize the treatment of adult patients with relapsed acute lymphoblastic leukemia, specifically blinatumomab and inotuzumab ozogamicin.

Combinations Key to Optimizing Novel Antibodies in Myeloma

November 4th 2015

Optimizing outcomes with novel antibodies in multiple myeloma will involve combination regimens with established agents.

European Commission Expands Azacitidine Approval in AML

October 30th 2015

The European Commission has expanded the approval of azacitidine in acute myeloid leukemia to include patients aged â‰¥65 years who are ineligible for hematopoietic stem cell transplantation and who have >30% myeloblasts.

PD-1 Immunotherapy Combos May Be Next Step in Hodgkin Lymphoma Therapy

October 29th 2015

The prospect of combining PD-1 inhibitors with existing therapies, particularly brentuximab vedotin, is emerging as the most exciting new development in advancing the treatment of patients with Hodgkin lymphoma, raising the possibility of improving the cure rates in a disease where standard strategies have already produced notable results.